Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart J C, Staels B, Auwerx J
U.325 INSERM, Département d'Athérosclérose, Institut Pasteur, Lille, France.
J Clin Invest. 1995 Aug;96(2):741-50. doi: 10.1172/JCI118118.
In view of the evidence linking plasma high density lipoprotein (HDL)-cholesterol levels to a protective effect against coronary artery disease and the widespread use of fibrates in the treatment of hyperlipidemia, the goal of this study was to analyze the influence of fibrates on the expression of apolipoprotein (apo) A-II, a major protein constituent of HDL. Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-II concentrations (0.34 +/- 0.11 to 0.45 +/- 0.17 grams/liter; P < 0.01). This increase in plasma apo A-II was due to a direct effect on hepatic apo A-II production, since fenofibric acid induced apo A-II mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively. The induction in apo A-II mRNA levels was followed by an increase in apo A-II secretion in both cell culture systems. Transient transfection experiments of a reporter construct driven by the human apo A-II gene promoter indicated that fenofibrate induced apo A-II gene expression at the transcriptional level. Furthermore, several other peroxisome proliferators, such as the fibrate, Wy-14643, and the fatty acid, eicosatetraynoic acid (ETYA), also induced apo A-II gene transcription. Unilateral deletions and site-directed mutagenesis identified a sequence element located in the J-site of the apo A-II promoter mediating the responsiveness to fibrates and fatty acids. This element contains two imperfect half sites spaced by 1 oligonucleotide similar to a peroxisome proliferator responsive element (PPRE). Cotransfection assays showed that the peroxisome proliferator activated receptor (PPAR) transactivates the apo A-II promoter through this AII-PPRE. Gel retardation assays demonstrated that PPAR binds to the AII-PPRE with an affinity comparable to its binding affinity to the acyl coA oxidase (ACO)-PPRE. In conclusion, in humans fibrates increase plasma apo A-II concentrations by inducing hepatic apo A-II production. Apo A-II expression is regulated at the transcriptional level by fibrates and fatty acids via the interaction of PPAR with the AII-PPRE, thereby demonstrating the pivotal role of PPAR in controlling human lipoprotein metabolism.
鉴于血浆高密度脂蛋白(HDL)胆固醇水平与预防冠状动脉疾病的保护作用之间存在关联,且贝特类药物在高脂血症治疗中广泛应用,本研究的目的是分析贝特类药物对HDL的主要蛋白质成分载脂蛋白(apo)A-II表达的影响。对16例冠状动脉疾病患者给予非诺贝特(300mg/d)治疗,导致血浆apo A-II浓度显著升高(从0.34±0.11克/升增至0.45±0.17克/升;P<0.01)。血浆apo A-II的这种升高是由于对肝脏apo A-II产生的直接作用,因为非诺贝特酸分别将人原代肝细胞和人肝癌HepG2细胞中apo A-II mRNA水平诱导至对照水平的450%和250%。在两种细胞培养系统中,apo A-II mRNA水平的诱导之后是apo A-II分泌的增加。由人apo A-II基因启动子驱动的报告构建体的瞬时转染实验表明,非诺贝特在转录水平诱导apo A-II基因表达。此外,其他几种过氧化物酶体增殖剂,如贝特类药物Wy-14643和脂肪酸二十碳四烯炔酸(ETYA),也诱导apo A-II基因转录。单向缺失和定点诱变确定了位于apo A-II启动子J位点的一个序列元件,该元件介导对贝特类药物和脂肪酸的反应性。该元件包含两个不完美的半位点,由1个寡核苷酸隔开,类似于过氧化物酶体增殖剂反应元件(PPRE)。共转染实验表明,过氧化物酶体增殖剂激活受体(PPAR)通过该AII-PPRE反式激活apo A-II启动子。凝胶阻滞实验表明,PPAR与AII-PPRE的结合亲和力与其与酰基辅酶A氧化酶(ACO)-PPRE的结合亲和力相当。总之,在人类中,贝特类药物通过诱导肝脏apo A-II的产生来增加血浆apo A-II浓度。贝特类药物和脂肪酸通过PPAR与AII-PPRE的相互作用在转录水平调节apo A-II的表达,从而证明PPAR在控制人类脂蛋白代谢中的关键作用。